Through its founder, Alfred Ajami, Ph.D., MassTrace and its predecessor companies have over 20 years of history in pharmaceutical, metabolism, biochemical, and nutrition research.
selected to present at BIO
CEO and BIO
2000 healthcare conferences. MassTrace biomarker technology selected by major Japanese pharmaceutical company for application in gastroenterology. MassTrace
enters collaborative commercialization agreement with Parexel International
, a major contract research organization.
and fellow researchers demonstrate arginine to citrulline conversion as a method for determining in vivo NO production
established as a focused business entity to continue the stable isotope product activities previously directed by Ajami
at Tracer Technologies
S Mossi et al publish gastric emptying breath test using Tracer Technologies 13C-acetate Szabo et al win McKeen-Cattell prize awarded annually by the American College of Clinical Pharmacology
for use of stable isotope tracers for mass balance (with analytical support from Ajami)
...MassTrace founder Alfred Ajami co-founds Tracer Technologies
publishes paper describing use of laser spectroscopy to measure 13CO2 in breath
1977 MassTrace founder Ajami gains his first commercial experience with stable and radio-isotopes as President of Kor Isotopes, later sold in 1979.
© 1999 MassTrace Inc